News | March 06, 2015

Post-Hoc Analyses of TRA-2°P Trial Show Efficacy of Zontivity with Aspirin and Clopidogrel

Combinations reduced acute limb ischemia and peripheral revascularizations, respectively, in certain patients with peripheral arterial disease.

March 6, 2015 — Merck announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of Zontivity (vorapaxar), one of the largest secondary prevention studies of an antiplatelet medicine. These data on additional endpoints in subgroups of patients with peripheral arterial disease (PAD) are being presented at the 2015 American College of Cardiology (ACC) Scientific Sessions, March 14-16, 2015, in San Diego.

Zontivity is indicated for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) or in patients with PAD. The May 2014 United States approval of Zontivity was based on the pivotal TRA 2°P TIMI 50 study, in which Zontivity was shown to reduce the rate of a combined endpoint of CV death, MI, stroke and urgent coronary revascularization (UCR) when added to aspirin and/or clopidogrel.

“As treating physicians, we are always concerned about our patients with PAD because of their risk for both systemic cardiovascular events as well as limb vascular events including acute limb ischemia and disease progression leading to peripheral revascularizations,” said Marc P. Bonaca, M.D., MPH, investigator, TIMI Study Group and associate physician at Brigham and Women’s Hospital and Harvard Medical School in Boston, Mass. “Because there are limited options available to reduce the risk of limb vascular events, these exploratory subgroup analyses raise important hypotheses regarding the role of Zontivity (vorapaxar) in the management of PAD.”

TRA 2°P TIMI 50 was a 26,449-patient, randomized, double-blind, placebo-controlled trial in which participants had a history of spontaneous MI within the prior two weeks to twelve months, ischemic stroke or documented (symptomatic) PAD. Patients were followed for up to four years, with a median follow-up of 2.5 years. Zontivity, when used daily with standard of care that included aspirin and/or a thienopyridine (principally clopidogrel), was superior to standard of care alone in reducing the incidence of both the primary combined endpoint of CV death, MI, stroke, and UCR and a key secondary composite endpoint of CV death, MI and stroke.

Data being presented at ACC include two post-hoc subgroup analyses that explored the use of Zontivity in certain patients with established PAD. PAD is generally defined as obstruction of arteries supplying the lower extremities, most commonly due to atherosclerosis. People with PAD are at increased risk for heart attack, stroke, and CV death. People with PAD are also at risk for complications from ischemia involving the lower extremities, and this was the focus of the two subgroup analyses being presented.

More specifically, these exploratory analyses looked at rates of:

1. Acute limb ischemia (ALI), a serious condition caused by an abrupt interruption of blood flow to a limb due to embolic or thrombotic vascular occlusion, which can result in limb loss.

2. Peripheral artery revascularization (PR), either a percutaneous (generally with stenting) or surgical procedure that restores blood flow to a limb that is supplied by blocked arteries.

For more information:

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Lesion Preparation Via Atherectomy Enhances Paclitaxel Distribution in Calcified Peripheral Arteries
News | Peripheral Artery Disease (PAD)| September 20, 2017
September 20, 2017 — Not-for-profit preclinical research institute CBSET announced that its scientists have published
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Overlay Init